AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) in partnership with EUSA Pharma has announced that it observed positive results from their ongoing Phase 1 study of tivozanib combined with nivolumab.
The two companies have reported that the phase 1 study has demonstrated potential upside in the treatment of advanced renal cell carcinoma. Nivolumab is a PD-1inhibitor from Bristol-Myers Squibb Co (NYSE:BMY). Aveo made the announcement on Friday revealing that the study has shown positive results. The firm revealed the results during the 16th International Kidney Cancer Symposium held in Miami.
The phase 1 clinical study involved 6 volunteering patients, three of whom were not previously treated using metastatic RCC while the other three had previously received treatment. The RCC tumor histology included one papillary and five clear cell. The patients in the trial were divided into two groups and the drugs were administered at 1.0 mg/QD and 1.5 mg/QD. The doses were also combined with a constant constant 240 mg of nivolumab which was administered every 2 weeks.
“Combining VEGF TKIs and PD-1s holds the potential for synergistic activity against renal cell carcinoma, yet most such combinations demonstrate a high rate of toxicity in the clinic,” stated Dr. Laurence Albiges, the lead investigator in the study.
Albiges also pointed out that Tivozanib possesses various distinguishing characteristics that boost its ability to combine with checkpoint inhibitors. They include types 1, 2, and 3 VEGF-Receptors and it is also able to decrease the regulatory T cells thus boosting its immune activity making it easier to fight the tumor. The doctor also stated that Tivozanib has also showcased good tolerability in the study and that the TiNivo study also demonstrated tolerable and promising activity.
Dr. Michael Needle, the chief medical officer at AVEO stated that the researchers involved in the preliminary study were encouraged by the activity and tolerability demonstrated by the results. He also stated that the positive results of the trial highlight the potential of the treatments which is quite encouraging for the firm. Needle also noted that immunotherapy combinations have continued to show positive outcomes in treating patients with RCC.
AVEO stock closed the latest trading session on Monday at $2.94 after tanking by 8.41 percent compared to the value of the stock during the previous close.